The Role of Pharmacotherapy in the Treatment of Adolescent Substance Use Disorders

Child and Adolescent Psychiatric Clinics of North America

Volumn 25, Issue 4, 2016, Pages 685-711

  Hammond, Christopher J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Addiction; Adolescence; Development; Medication; Pharmacotherapy; Substance use disorder

Indexed keywords

ACETYLCYSTEINE; AMFEBUTAMONE; BENZODIAZEPINE DERIVATIVE; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; CLONIDINE; DISULFIRAM; METHADONE; NALOXONE; NALTREXONE; NICOTINE; ONDANSETRON; TOPIRAMATE; VARENICLINE;

ADOLESCENT; ADULT; ALCOHOL WITHDRAWAL SYNDROME; ALCOHOLISM; BRAIN DEVELOPMENT; CANNABIS ADDICTION; DRUG DEPENDENCE TREATMENT; EVIDENCE BASED MEDICINE; HUMAN; INTOXICATION; MAINTENANCE THERAPY; NICOTINE REPLACEMENT THERAPY; OPIATE ADDICTION; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME; PSYCHOLOGY; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

ADOLESCENT; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 84996549885     PISSN: 10564993     EISSN: 15580490     Source Type: Journal    
DOI: 10.1016/j.chc.2016.05.004     Document Type: Review

References (106)

1. 1 Uhl, G.R., Grow, R.W., The burden of complex genetic brain disorders. Arch Gen Psychiatry 61 (2004), 223–229.
2. 2 Healthday, Addiction starts early in American Society. US News World Rep, 2011 Available at: http://consumer.healthday.com/mental-health-information-25/addiction-news-6/addiction-starts-early-in-american-society-report-finds-654435.html Accessed March 1, 2016.
3. 3 Eaton, L.K., Kann, I., Kinchen, S., Youth risk behavior surveillance—United States: 2007, surveillance summaries. MMWR Surveill Summ 57:SS04 (2008), 1–131.
4. 4 Tarter, R.E., Vanyukov, M., Alcoholism: a developmental disorder. J Consult Clin Psychol 62:6 (1994), 1096–1107.
5. 5 Lopez-Quintero, C., Perez de los Cobos, J., Hasin, D.S., et al. Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Drug Alcohol Depend 115:1–2 (2011), 120–130.
6. 6 Wagner, F.A., Anthony, J.C., From first drug use to drug dependence - developmental periods of risk for dependence upon marijuana, cocaine, and alcohol. Neuropharmacology 26:4 (2002), 479–488.
7. 7 Centers for Disease Control and Prevention (CDC), Mental health surveillance among children - United States, 2005-2011. MMWR 62:Suppl 2 (2013), 1–17.
8. 8 Arendt, M., Munk-Jorgensen, P., Sher, L., et al. Mortality among individuals with cannabis, cocaine, amphetamine, MDMA, and opioid use disorders: a nationwide follow-up study of Danish substance users in treatment. Drug Alcohol Depend 114:2–3 (2011), 134–139.
9. 9 Hall, W., Solowij, N., Adverse effects of cannabis. Lancet 352:9140 (1998), 1611–1616.
10. 10 Volkow, N.D., Baler, R.D., Compton, W.M., et al. Adverse health effects of marijuana use. N Engl J Med 370:23 (2014), 2219–2227.
11. 11 Lisdahl, K.M., Gilbart, E.R., Wright, N.E., et al. Dare to delay? The impacts of adolescent alcohol and marijuana use onset on cognition, brain structure, and function. Front Psychiatry, 4, 2013, 53.
12. 12 Substance Abuse and Mental Health Services Administration (SAMHSA), Results from the 2013 National survey on drug use and health: summary of national findings. 2014, Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville (MD).
13. 13 Substance Abuse and Mental Health Services Administration (SAMHSA), Treatment episode data set (TEDS): 2002-2012. National admissions to substance abuse treatment services. 2014, Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville (MD).
14. 14 Waldron, H.B., Turner, C.W., Evidence-based psychosocial treatments for adolescent substance abuse. J Clin Child Adolesc Psychol 37:1 (2008), 238–261.
15. 15 Winters, K.C., Tanner-Smith, E.E., Bresani, E., et al. Current advances in the treatment of adolescent drug use. Adolesc Health Med Ther 5 (2014), 199–210.
16. 16 Stanger, C., Budney, A.J., Contingency management approaches for adolescent substance use disorders. Child Adolesc Psychiatr Clin N Am 19:3 (2010), 547–562.
17. 17 Stanger, C., Ryan, S.R., Scherer, E.A., et al. Clinic- and home-based contingency management plus parent training for adolescent cannabis use disorders. J Am Acad Child Adolesc Psychiatry 54:6 (2015), 445–453.e2.
18. 18 Dennis, M., Godley, S.H., Diamond, G., et al. The Cannabis Youth Treatment (CYT) Study: main findings from two randomized trials. J Subst Abuse Treat 27:3 (2004), 197–213.
19. 19 Cornelius, J.R., Maisto, S.A., Pollock, N.K., et al. Rapid relapse generally follows treatment for substance use disorders among adolescents. Addict Behav 28 (2003), 381–386.
20. 20 Brown, P.C., Budney, A.J., Thostenson, J.D., et al. Initiation of abstinence in adolescents treated for marijuana use disorders. J Subst Abuse Treat 44:4 (2013), 384–390.
21. 21 Mann C, Frieden T, Hyde PS, et al. Medication assisted treatment for substance use disorders. Center for Medicaid and CHIP services information bulletin. 2014. Available at: www.medicaid.gov/federal-policy-guidance/downloads/cib-07-11-2014.pdf. Accessed January 15, 2016.
22. 22 Volkow, N.D., Frieden, T., Hyde, P.S., et al. Medication-assisted therapies - tackling the opioid-overdose epidemic. N Engl J Med 370:22 (2014), 2063–2066.
23. 23 Center for Substance Abuse Treatment, Incorporating alcohol pharmacotherapies into medical practice. Vol HHS Publ No. (SMA) 09–4380, 2009, Substance Abuse and Mental Health Services Administration, Rockville (MD).
24. 24 Fiore, M.C., Jaen, C.R., Tobacco Use and Dependence Guideline Panel. Treating tobacco use and dependence: 2008 update. 2008, US Department of Health and Human Services, Rockville, MD, 106–130.
25. 25 Thomas, C.P., Fullerton, C.A., Kim, M., et al. Medication-assisted treatment with buprenorphine: assessing the evidence. Psychiatr Serv 65:2 (2014), 158–170.
26. 26 Fullerton, C.A., Kim, M., Thomas, C.P., et al. Medication-assisted treatment with methadone: assessing the evidence. Psychiatr Serv 65:2 (2014), 146–157.
27. 27 Holder, H.D., Costs benefits of substance abuse treatment: an overview of results from alcohol and drug abuse. J Ment Health Policy Econ 1:1 (1998), 23–29.
28. 28 Jones, H.E., Kaltenbach, K., Heil, S.H., Neonatal abstinence syndrome after methadone or buprenorpine exposure. N Engl J Med 363 (2010), 2320–2331.
29. 29 Baser, O., Chalk, M., Rawson, R., et al. Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence. Am J Manag Care 17 (2011), 222–234.
30. 30 Deas, D., Riggs, P.R., Langenbucher, J., et al. Adolescents are not adults: developmental considerations in alcohol users. Alcohol Clin Exp Res 24:2 (2000), 232–237.
31. 31 Hammond, C.J., Mayes, L.C., Potenza, M.N., Neurobiology of adolescent substance use and addictive behaviors: prevention and treatment implications. Adolesc Med State Art Rev 25:1 (2014), 15–32.
32. 32 Fernandez, E., Perez, R., Hernandez, A., et al. Factors and mechanisms for pharmacokinetic differences between pediatric population and adults. Pharmaceutics 3:1 (2011), 53–72.
33. 33 Vitiello, B., Developmental aspects of pediatric psychopharmacology. Findling, R.L., (eds.) Clinical manual of child & adolescent psychopharmacology, 2008, American Psychiatric Association, Arlington (VA), 1–31.
34. 34 van den Anker, J.N., Schwab, M., Kearns, G.L., Developmental pharmacokinetics. Handb Exp Pharmacol 205 (2011), 51–75.
35. 35 Paus, T., Keshavan, M., Giedd, J.N., Why do so many psychiatric disorders emerge during adolescence?. Nat Neurosci 9 (2008), 947–957.
36. 36 Shaw, P., Kabani, N.J., Lerch, J.P., et al. Neurodevelopmental trajectories of the human cerebral cortex. J Neurosci 28:14 (2008), 3586–3594.
37. 37 Vitiello, B., Pediatric psychopharmacology and the interaction between drugs and the developing brain. Can J Psychiatry 43:6 (1998), 582–584.
38. 38 Spear, L.P., Adolescent alcohol exposure: are there separable vulnerable periods within adolescence?. Physiol Behav 148 (2015), 122–130.
39. 39 Cui, C., Noronha, A., Morikawa, H., et al. New insights on neurobiological mechanisms underlying alcohol addiction. Neuropharmacology 67 (2013), 223–232.
40. 40 Hammond, C.J., Niciu, M.J., Drew, S., et al. Anticonvulsants for the treatment of alcohol withdrawal syndrome and alcohol use disorders. CNS Drugs 29:4 (2015), 293–311.
41. 41 Clark, D.B., Pharmacotherapy for adolescent alcohol use disorders. CNS Drugs 26:7 (2012), 559–569.
42. 42 Martin, C.S., Kaczynski, N.A., Maisto, S.A., et al. Patterns of DSM-IV alcohol abuse and dependence symptoms in adolescent drinkers. J Stud Alcohol 56 (1998), 672–680.
43. 43 Mayo-Smith, M.F., Pharmacological management of alcohol withdrawal: a meta-analysis and evidence based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. JAMA 287:2 (1997), 144–151.
44. 44 The National Clinical Guideline Centre for acute and Chronic Conditions, Alcohol use disorders: diagnosis and clinical management of alcohol-related physical complications. Clinical guideline 100. 2010, National Clinical Guidelines Centre at the Royal College of Physicians, London (United Kingdom).
45. 45 Bouza, C., Angeles, M., Munoz, A., et al. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 99:7 (2004), 811–828.
46. 46 Roozen, H.G., de Waart, R., van der Windt, D.A., et al. A systematic review of the effectiveness of naltrexone in the maintenance treatment of opioid and alcohol dependence. Eur Neuropsychopharmacol 16:5 (2006), 311–323.
47. 47 Monti, P.M., Rohsenow, D.J., Hutchinson, K.E., et al. Naltrexone's effect on cue-elicited craving among alcoholics in treatment. Alcohol Clin Exp Res 23:8 (1999), 1386–1394.
48. 48 Deas, D., May, K., Randall, C.L., et al. Naltrexone treatment of adolescent alcoholics: an open-label pilot study. J Child Adolesc Psychopharmacol 15:5 (2005), 723–728.
49. 49 Miranda, R., Ray, L., Blanchard, A., et al. Effects of naltrexone on adolescent alcohol cue reactivity and sensitivity: an initial randomized trial. Addict Biol 19:5 (2014), 941–954.
50. 50 Schroeder, J.P., Cooper, D.A., Schank, J.R., et al. Disulfiram attenuates drug-primed reinstatement of cocaine seeking via inhibition of dopamine beta-hydroxylase. Neuropsychopharmacology 35:12 (2010), 2440–2449.
51. 51 Niederhofer, H., Staffen, W., Comparison of disulfiram and placebo in treatment of alcohol dependence of adolescents. Drug Alcohol Rev 22:3 (2003), 295–297.
52. 52 Kranzler, H.R., Pierucci-Lagha, A., Feinn, R., et al. Effects of ondansetron in early- versus late-onset alcoholics: a prospective, open-label study. Alcohol Clin Exp Res 27:7 (2003), 1150–1155.
53. 53 Johnson, B.A., Roache, J.D., Javors, M.A., Ondansetron for reduction of drinking among biologically predisposed alcohol patients: a randomized controlled trial. JAMA 284:8 (2000), 963–971.
54. 54 Johnson, B.A., Roache, J.D., Ait-Daoud, N., et al. Ondansetron reduces the craving of biologically predisposed alcoholics. Psychopharmacology (Berl) 160:4 (2002), 408–413.
55. 55 Johnson, B.A., Ait-Daoud, N., Seneviratne, C., et al. Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am J Psychiatry 168:3 (2011), 265–275.
56. 56 White, H.S., Mechanism of action of newer anticonvulsants. J Clin Psychiatry 64:Suppl 8 (2004), 5–8.
57. 57 Perucca, E., Clinical pharmacology and therapeutic use of the new antiepileptic drugs. Fundam Clin Pharmacol 15 (2001), 405–417.
58. 58 Monti, P.M., Miranda, R., Justus, A., et al. Biobehavioral mechanisms of topiramate and drinking in adolescents: preliminary findings. Neuropharmacology, 35, 2010, S164.
59. 59 Backinger, C.L., Fagan, P., Matthews, E., et al. Adolescent and young adult tobacco prevention and cessation: current status and future directions. Tob Control 12:Suppl IV (2003), iv46–iv53.
60. 60 Kim, Y., Myung, S.K., Jeon, Y.J., et al. Effectiveness of pharmacologic therapy for smoking cessation in adolescent smokers: meta-analysis of randomized controlled trials. Am J Health Syst Pharm 68:3 (2011), 219–226.
61. 61 Hanson, K., Allen, S., Jensen, S., et al. Treatment of adolescent smokers with the nicotine patch. Nicotine Tob Res 5:4 (2003), 514–526.
62. 62 Moolchan, E.T., Robinson, M.L., Ernst, M., et al. Safety and efficacy of the nicotine patch and gum for the treatment of adolescent tobacco addiction. Pediatrics 115:4 (2005), e407–414.
63. 63 Scherphof, C.S., van den Eijnden, R.J., Engels, R.C., et al. Short-term efficacy of nicotine replacement therapy for smoking cessation in adolescents: a randomized controlled trial. J Subst Abuse Treat 46:2 (2014), 120–127.
64. 64 Scherphof, C.S., van den Eijnden, R.J., Engels, R.C., et al. Long-term efficacy of nicotine replacement therapy for smoking cessation in adolescents: a randomized controlled trial. Drug Alcohol Depend 140 (2014), 217–220.
65. 65 Scherphof, C.S., van den Eijnden, R.J., Lugtig, P., et al. Adolescents' use of nicotine replacement therapy for smoking cessation: predictors of compliance trajectories. Psychopharmacology (Berl) 231:8 (2014), 1743–1752.
66. 66 Rubinstein, M.L., Benowitz, N.L., Auerback, G.M., et al. A randomized trial of nicotine nasal spray in adolescent smokers. Pediatrics 122:3 (2008), e595–600.
67. 67 Warner, C., Shoaib, M., How does bupropion work as a smoking cessation aid?. Addict Biol 10:3 (2005), 219–231.
68. 68 Killen, J.D., Robinson, T.N., Ammerman, S., et al. Randomized clinical trial of the efficacy of bupropion combined with nicotine patch in the treatment of adolescent smokers. J Consult Clin Psychol 72:4 (2004), 729–735.
69. 69 Muramoto, M.L., Leischow, S.J., Sherill, D., et al. Randomized double-blind, placebo controlled trial of 2 dosages of sustained-release bupropion for adolescent smoking cessation. Arch Pediatr Adolesc Med 161 (2007), 1068–1074.
70. 70 Leischow, S.J., Muramoto, M.L., Matthews, E., et al. Adolescent smoking cessation with bupropion: the role of adherence. Nicotine Tob Res 18:5 (2016), 1202–1205.
71. 71 Gray, K.M., Carpenter, M.J., Baker, N.L., et al. Bupropion SR and contingency management for adolescent smoking cessation. J Subst Abuse Treat 40:1 (2011), 77–86.
72. 72 Cahill, K., Stead, L.F., Lancaster, T., Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev(4), 2012 CD006103. 1–121.
73. 73 Faessel, H.M., Obach, R.S., Rollema, H., et al. A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessation. Clin Pharmacokinet 49:12 (2010), 799–816.
74. 74 Gray, K.M., Carpenter, M.J., Lewis, A.L., et al. Varenicline versus bupropion XL for smoking cessation in older adolescents: a randomized, double-blind pilot trial. Nicotine Tob Res 14:2 (2012), 234–239.
75. 75 Thomas, K.H., Martin, R.M., Davies, N.M., et al. Smoking cessation treatment and risk of depression, suicide, and self harm in the Clinical Practice Research Datalink: prospective cohort study. BMJ, 347, 2013, f5704.
76. 76 Suarez, I., Bodega, G., Fernandez-Ruiz, J., et al. Down-regulation of the AMPA glutamate receptor subunits GLUR1 and GLUR2/3 in the rat cerebellum following pre- and perinatal delta-9-tetrahydrocanninol exposure. Cerebellum 2 (2003), 66–74.
77. 77 Behan, A.T., Hryniewiecka, M., O'Tuathaigh, C.M., et al. Chronic adolescent exposure to delta-9-tetrahydrocannabinol in COMT mutant mice: impact on indices of dopaminergic, endocannabinoid and GABAergic pathways. Neuropsychopharmacology 37:7 (2012), 1773–1783.
78. 78 Moreira, F.A., Jupp, B., Belin, D., et al. Endocannabinoids and striatal function: implications for addiction-related behaviours. Behav Pharmacol 26:1–2 (2015), 59–72.
79. 79 Gray, K.M., Watson, N.L., Carpenter, M.J., et al. N-acetylcysteine (NAC) in young marijuana users: an open-label pilot study. Am J Addict 19:2 (2010), 187–189.
80. 80 Gray, K.M., Carpenter, M.J., Baker, N.L., et al. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatry 169:8 (2012), 805–812.
81. 81 Mason, B.J., Crean, R., Goodell, V., et al. A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology 37:7 (2012), 1689–1698.
82. 82 Lewerenz, J., Hewett, S.J., Huang, Y., et al. The cysteine/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities. Antioxid Redox Signal 18:5 (2013), 522–555.
83. 83 Baker, D.A., McFarland, K., Lake, R.W., et al. Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. Nat Neurosci 6:7 (2003), 743–749.
84. 84 Deepmala, Slattery, J., Kumar, N., et al. Clinical trials of N-acetylcysteine in psychiatry and neurology: a systematic review. Neurosci Biobehav Rev 55 (2015), 294–321.
85. 85 McClure, E.A., Sonne, S.C., Winhusen, T., et al. Achieving cannabis cessation – evaluating N-acetylcysteine treatment (ACCENT): design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network. Contemp Clin Trials 39:2 (2014), 211–223.
86. 86 Miranda, R. Jr., Treloar, H., Blanchard, A., et al. Topiramate and motivational enhancement therapy for cannabis use among youth: a randomized placebo-controlled pilot study. Addiction Biology, 2016 [Epub ahead of print].
87. 87 Fiellin, D.A., Treatment of adolescent opioid dependence: no quick fix. JAMA 300:17 (2008), 2057–2059.
88. 88 Subramaniam, G.A., Stitzer, M.L., Woody, G., et al. Clinical characteristics of treatment-seeking adolescents with opioid versus cannabis/alcohol use disorders. Drug Alcohol Depend 99:1–3 (2009), 141–149.
89. 89 Mattick, R.P., Breen, C., Kimber, J., et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev, 2, 2014, CD002207.
90. 90 Mattick, R.P., Breen, C., Kimber, J., et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev(3), 2009 CD002209. 1–34.
91. 91 Stotts, A.L., Dodrill, C.L., Kosten, T.R., Opioid dependence treatment: options in pharmacotherapy. Expert Opin Pharmacother 10:11 (2009), 1727–1740.
92. 92 Marsch, L., Bickel, W.K., Badger, G.L., et al. Comparison of pharmacological treatments for opioid-dependent adolescents. Arch Gen Psychiatry 62 (2005), 1157–1164.
93. 93 Woody, G., Poole, S.A., Subramaniam, G., et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth. JAMA 300:17 (2008), 2003–2011.
94. 94 Minozzi, S., Amato, L., Bellisario, C., et al. Detoxification treatments for opiate dependent adolescents. Cochrane Database Syst Rev(4), 2014 CD006749. 1–36.
95. 95 Minozzi, S., Amato, L., Bellisario, C., et al. Maintenance treatments for opiate-dependent adolescents. Cochrane Database Syst Rev(6), 2014 CD007210. 1–34.
96. 96 Lowinson, J.H., Marion, I.L., Joseph, H., et al. Methadone maintenance. Lowinson, J.H., Ruiz, P., Millman, R.B., (eds.) Substance abuse: a comprehensive textbook, 2nd edition, 1992, Williams and Wilkins, Baltimore (MD), 405–414.
97. 97 Hopfer, C.J., Khuri, E., Crowley, T.J., Treating adolescent heroin use. J Am Acad Child Adolesc Psychiatry 42:5 (2003), 609–611.
98. 98 Sells, S.B., Simpson, D.D., Evaluation of treatment outcome for youths in the drug abuse reporting program (DARP): a followup study. Beschner, G.M., Friedman, A.S., (eds.) Youth drug abuse: problems, issues, and treatment, 1979, Lexington Books, Lexington (MA), 571–628.
99. 99 Subramaniam, G., Warden, D., Minhajuddin, A., et al. Predictors of abstinence: National Institute on Drug Abuse multisite buprenorphine/naloxone treatment trial in opioid-dependent youth. J Am Acad Child Adolesc Psychiatry 50:11 (2011), 1120–1128.
100. 100 Fishman, M.J., Winstanley, E.L., Curran, E., et al. Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: preliminary case-series and feasibility. Addiction 105:9 (2010), 1669–1676.
101. 101 Centers for Disease Control and Prevention. National vital statistics system mortality data. 2015. Available at: www.cdc.gov/nchs/deaths.htm.
102. 102 World Health Organization (WHO), Community management of opioid overdose. 2014, WHO Press, Geneva (Switzerland).
103. 103 US Food and Drug Administration (FDA). FDA moves quickly to approve easy-to-use nasal spray to treat opioid overdose 2015; FDA Informational Bulletin. Available at: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm473505.htm. Accessed January 15, 2016.
104. 104 Substance Abuse and Mental Health Services Administration (SAMHSA), SAMHSA Opioid overdose prevention toolkit. 2014, Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville (MD) Vol HHS Publ No. (SMA) 14–4742.
105. 105 O'Farrell, T.J., Bayog, R.D., Antabuse contracts for married alcoholics and their spouses: a method to maintain antabuse ingestion and decrease conflict about drinking. J Subst Abuse Treat 3 (1986), 1–8.
106. 106 Ebell, M.H., Siwek, J., Weiss, B.D., et al. Simplifying the language of evidence to improve patient care: strength of Recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. J Fam Pract 53:2 (2010), 111–120.